Home Cart Sign in  
Chemical Structure| 83570-42-7 Chemical Structure| 83570-42-7

Structure of 83570-42-7

Chemical Structure| 83570-42-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 83570-42-7 ]

CAS No. :83570-42-7
Formula : C10H8N2O
M.W : 172.18
SMILES Code : CC(C1=CC=C2N=CC=NC2=C1)=O
MDL No. :MFCD09880611
InChI Key :DZJNWCSVQXNMFO-UHFFFAOYSA-N
Pubchem ID :22631249

Safety of [ 83570-42-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 83570-42-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 10
Fraction Csp3 0.1
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 49.73
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

42.85 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.57
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.27
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.83
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.53
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.25
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.49

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.21
Solubility 1.06 mg/ml ; 0.00615 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.77
Solubility 2.93 mg/ml ; 0.017 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.66
Solubility 0.0378 mg/ml ; 0.000219 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.45 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.38

Application In Synthesis of [ 83570-42-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 83570-42-7 ]

[ 83570-42-7 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 50998-17-9 ]
  • [ 97674-02-7 ]
  • [ 83570-42-7 ]
References: [1] Patent: US2005/256309, 2005, A1, . Location in patent: Page/Page column 35.
[2] Patent: US2005/272736, 2005, A1, . Location in patent: Page/Page column 35.
[3] Patent: WO2016/30443, 2016, A1, . Location in patent: Page/Page column 80.
[4] Patent: WO2017/144633, 2017, A1, . Location in patent: Page/Page column 95.
[5] Patent: WO2017/144639, 2017, A1, . Location in patent: Page/Page column 80.
  • 2
  • [ 875558-38-6 ]
  • [ 75-16-1 ]
  • [ 83570-42-7 ]
YieldReaction ConditionsOperation in experiment
75.7% at 0 - 20℃; for 2 h; Inert atmosphere To a solution of Compound 2 (1 g, 4.6 mmol) in dry THF (10 mL) at 0 °C under N2 was added MeMgBr (2 mL, 3.0 mol/L, 6 mmol) dropwise. The resulting solution was slowly warm to RT over 2 hours. The mixture was diluted with NH4C1 solution and extracted with EA. The organic extracts were concentrated to give a crude oil. The crude product was purified by silica gel chromatography to afford Compound 3 (600 mg, 75.7 percent).
74% at 0 - 20℃; for 3 h; A mixture of quinoxaline-6-carboxylic acid (2 g, 11.49 mmol) and thionyl chloride (30 mL) was stirred at reflux for 2 hours. The reaction mixture was concentrated to dryness using a rotary evaporator to afford quinoxaline-6- EPO <DP n="101"/>carboxylic acid chloride (crude quantitative). A solution of the above acid chloride (11.49 mmol) in DCM (50 mL) and pyridine (20 mL) was mixed with N,O-dimethyl hydroxylamine HCI salt (2.24 g, 23 mmol) and stirred at room temperature for 12 hours. The reaction was quenched by adding aqueous HCI (50 mL, 1 N), extracted with DCM (3x100 mL), concentrated using a rotary evaporator. The residue was further purified by column (Siψ2, Hexanes/EtOAc = 1 :3) to yield quinoxaline-6-carboxylic acid methoxy-methyl-amide (2 g, 80percent). To a solution of the above Weinreb amide (2.0 g, 9.2 mmol) in THF (30 mL) at O0C was added methyl magnesium bromide (3.9 mL, 11.6 mmol). The reaction mixture was stirred at O0C for 2 hours and then 1 hour at room temperature, quenched by adding aqueous HCI (20 mL, 1 N), extracted with DCM (3x100 mL), concentrated using a rotary evaporator. The residue was further-purified by column (SiO2, Hexanes/EtOAc = 1 :3) to yield 6-acetylquinoxaline (1.17 g, 74percent). A solution of 2- chloronicotinic acid ethyl ester (5.0 g, 27 mmol) in MeOH (25 mL) was mixed with sodium methoxide (25.6 mL, 112.5 mmol) and stirred at reflux for 12 hours. The reaction was quenched by adding water (100 mL), extracted with DCM (3x100 mL), concentrated using a rotary evaporator to afford 2-methoxynicotinic acid methyl ester (3.2 g, 71percent). A solution of 6-acetylquinoxaline (0.62 g, 3.6 mmol), 2- methoxynicotinic acid methyl ester (0.64 g, 3.8 mmol), and sodium hydride (0.46 g, 11.4 mmol) in THF (100 mL) was stirred at room temperature for 16 hours. The reaction was quenched by adding water (100 mL) and AcOH (20 mL), extracted with dichloromethane (3x100 mL), and concentrated using a rotary evaporator. The residue was re-dissolved in DCM (5 mL) and MeOH (3 mL) and was diluted with Hexanes (50 mL). The solid was removed by filtration and the filtrate was concentrated to afford the diketo compound (0.7 g, 60percent). A solution of the above diketone (0.4 g, 1.3 mmol) in AcOH (50 mL) and sulfuric acid (cone, 15 drops) was stirred at reflux for 1 hour. Most of the solvent was removed using a rotary evaporator. The residue was re-dissolved in MeOH and neutralized with potassium carbonate to pH = 8. The solid residue was removed by filtration, washed with MeOH and DCM. The filtrate was extracted with CH2CI2 (3x100 mL) and concentrated using a rotary evaporator. The solid residue was purified by column (SiO2, Hexanes/EtOAc/MeOH = 2:2:1) to afford 2-(quinoxalin-6-yl)-4H- EPO <DP n="102"/>pyrano[2,3-b]pyridin-4-one (90 mg, 24percent); MS (ES) m/z: 276 (M+1 ); MP 272.3- 274.80C
References: [1] Patent: WO2016/77232, 2016, A2, . Location in patent: Page/Page column 25; 33; 35; 37.
[2] Patent: WO2007/16525, 2007, A2, . Location in patent: Page/Page column 99-101.
  • 3
  • [ 50998-17-9 ]
  • [ 83570-42-7 ]
YieldReaction ConditionsOperation in experiment
45% With bis-triphenylphosphine-palladium(II) chloride In toluene at 20 - 90℃; To a degassed stirred solution of 6-bromo quinoxaline (2.0 g, 9.50 mmol) in toluene (20 mL), 1- ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) followed by Pd(PPh3)2CI2 (0.67 g, 0.95 mmol) were added at RT and stirred at 90 °C overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT, filtered through celite and the obtained filtrate was evaporated under vacuum. To the resulting crude mixture, 6 N HCI solution (20 mL) was added and the mixture was stirred at RT for 1 h. The solution was neutralized with sat. NaHC03 and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layer was dried over Na2S04 and concentrated under vacuum. The resulting crude material was purified by flash chromatography (Biotage Isolera, eluent: 30percent EtOAc in hexane) to afford the title compound. Yield: 45percent (800 mg, brown solid). 1H NMR (400 MHz, DMSO-tf6): δ 9.06-9.04 (m, 2H), 8.70 (d, J = 2.4 Hz, 1 H), 8.28 (dd, J = 8.8, 2.8 Hz, 1 H), 8.16 (d, J = 8.4 Hz, 1 H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.2 min, 99.1 percent (Max).
References: [1] Patent: WO2019/37860, 2019, A1, . Location in patent: Page/Page column 68.
  • 4
  • [ 6925-00-4 ]
  • [ 83570-42-7 ]
References: [1] Patent: WO2016/77232, 2016, A2, .
  • 5
  • [ 1432-42-4 ]
  • [ 83570-42-7 ]
References: [1] Journal of the Chemical Society, 1956, p. 2058,2060.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 83570-42-7 ]

Ketones

Chemical Structure| 56234-20-9

A117921 [56234-20-9]

1-(Quinolin-8-yl)ethanone

Similarity: 0.75

Chemical Structure| 99-03-6

A136182 [99-03-6]

1-(3-Aminophenyl)ethanone

Similarity: 0.70

Chemical Structure| 99-92-3

A206379 [99-92-3]

1-(4-Aminophenyl)ethanone

Similarity: 0.69

Chemical Structure| 1122-54-9

A284316 [1122-54-9]

4-Acetylpyridine

Similarity: 0.68

Chemical Structure| 53400-41-2

A156644 [53400-41-2]

7,8-Dihydroquinolin-5(6H)-one

Similarity: 0.68

Related Parent Nucleus of
[ 83570-42-7 ]

Quinoxalines

Chemical Structure| 130345-50-5

A148009 [130345-50-5]

Quinoxaline-6-carbaldehyde

Similarity: 0.91

Chemical Structure| 141234-08-4

A415664 [141234-08-4]

Quinoxaline-5-carbaldehyde

Similarity: 0.86

Chemical Structure| 6925-00-4

A152455 [6925-00-4]

Quinoxaline-6-carboxylic acid

Similarity: 0.77

Chemical Structure| 6344-72-5

A173049 [6344-72-5]

6-Methylquinoxaline

Similarity: 0.76

Chemical Structure| 1233318-23-4

A169952 [1233318-23-4]

Methyl 2-(quinoxalin-6-yl)acetate

Similarity: 0.74